Cargando…

Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study

BACKGROUND: Intrapleural analgesia has been increasingly recommended for postoperative analgesia after thoracic surgery. However, the analgesic effect provided by a single intrapleural administration is time limited. This study reports the efficacy and safety of repeated intrapleural 0.75% ropivacai...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuanqing, Cai, Yaoyao, Ye, Yingchao, Xia, Yun, Papadimos, Thomas J, Liu, Le, Xu, Xuzhong, Wang, Quanguang, Shi, Kejian, Wu, Yiquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989531/
https://www.ncbi.nlm.nih.gov/pubmed/33776475
http://dx.doi.org/10.2147/JPR.S295913
_version_ 1783668953771409408
author Chen, Yuanqing
Cai, Yaoyao
Ye, Yingchao
Xia, Yun
Papadimos, Thomas J
Liu, Le
Xu, Xuzhong
Wang, Quanguang
Shi, Kejian
Wu, Yiquan
author_facet Chen, Yuanqing
Cai, Yaoyao
Ye, Yingchao
Xia, Yun
Papadimos, Thomas J
Liu, Le
Xu, Xuzhong
Wang, Quanguang
Shi, Kejian
Wu, Yiquan
author_sort Chen, Yuanqing
collection PubMed
description BACKGROUND: Intrapleural analgesia has been increasingly recommended for postoperative analgesia after thoracic surgery. However, the analgesic effect provided by a single intrapleural administration is time limited. This study reports the efficacy and safety of repeated intrapleural 0.75% ropivacaine administration after thoracoscopic surgery. METHODS: Twenty patients were randomly divided into two groups: a single administration group receiving a single intrapleural injection of 0.75% ropivacaine 15 mL (single administration group, SA group), and a repeated administration group with an intrapleural injection of 0.75% ropivacaine 15 mL every 4h for 4 doses (repeated administration group, RA group). The primary outcomes of this study were the peak plasma concentration of ropivacaine and 24h morphine consumption. The secondary outcomes were pain score, patient satisfaction, extubation time, hospital length of stay, and adverse reactions. RESULTS: In SA group, the highest plasma concentration after intrapleural administration of 0.75% ropivacaine 15 mL was 1345±364 μg/L. The highest plasma concentration in RA group after the fourth administration was 1864±492 μg/L. The 24h morphine consumption in RA group was significantly less than that in SA group (9.0±5.66 vs 15.9±3.48 mg, P=0.004). The NRS scores at rest and while coughing of patients in RA group were significantly lower than those in SA group at 5, 9, 13, 17 and 24h after operation. The patients in RA group had higher satisfaction than those in SA group. There was no significant difference in postoperative adverse events, drainage tube placement days and hospital length of stay between the two groups. CONCLUSION: Repeated intrapleural administration with 0.75% ropivacaine, 15 mL every 4h for 4 doses after video-assisted thoracoscopic lobectomies, can provide a more durable and more effective analgesic effect than single intrapleural administration. Repeated intrapleural administration of ropivacaine is an effective postoperative method of analgesia resulting in higher patient satisfaction. Moreover, it was also able to keep the plasma concentration of ropivacaine within a possible safe range. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-IOR-17010560.
format Online
Article
Text
id pubmed-7989531
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79895312021-03-25 Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study Chen, Yuanqing Cai, Yaoyao Ye, Yingchao Xia, Yun Papadimos, Thomas J Liu, Le Xu, Xuzhong Wang, Quanguang Shi, Kejian Wu, Yiquan J Pain Res Clinical Trial Report BACKGROUND: Intrapleural analgesia has been increasingly recommended for postoperative analgesia after thoracic surgery. However, the analgesic effect provided by a single intrapleural administration is time limited. This study reports the efficacy and safety of repeated intrapleural 0.75% ropivacaine administration after thoracoscopic surgery. METHODS: Twenty patients were randomly divided into two groups: a single administration group receiving a single intrapleural injection of 0.75% ropivacaine 15 mL (single administration group, SA group), and a repeated administration group with an intrapleural injection of 0.75% ropivacaine 15 mL every 4h for 4 doses (repeated administration group, RA group). The primary outcomes of this study were the peak plasma concentration of ropivacaine and 24h morphine consumption. The secondary outcomes were pain score, patient satisfaction, extubation time, hospital length of stay, and adverse reactions. RESULTS: In SA group, the highest plasma concentration after intrapleural administration of 0.75% ropivacaine 15 mL was 1345±364 μg/L. The highest plasma concentration in RA group after the fourth administration was 1864±492 μg/L. The 24h morphine consumption in RA group was significantly less than that in SA group (9.0±5.66 vs 15.9±3.48 mg, P=0.004). The NRS scores at rest and while coughing of patients in RA group were significantly lower than those in SA group at 5, 9, 13, 17 and 24h after operation. The patients in RA group had higher satisfaction than those in SA group. There was no significant difference in postoperative adverse events, drainage tube placement days and hospital length of stay between the two groups. CONCLUSION: Repeated intrapleural administration with 0.75% ropivacaine, 15 mL every 4h for 4 doses after video-assisted thoracoscopic lobectomies, can provide a more durable and more effective analgesic effect than single intrapleural administration. Repeated intrapleural administration of ropivacaine is an effective postoperative method of analgesia resulting in higher patient satisfaction. Moreover, it was also able to keep the plasma concentration of ropivacaine within a possible safe range. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-IOR-17010560. Dove 2021-03-19 /pmc/articles/PMC7989531/ /pubmed/33776475 http://dx.doi.org/10.2147/JPR.S295913 Text en © 2021 Chen et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Chen, Yuanqing
Cai, Yaoyao
Ye, Yingchao
Xia, Yun
Papadimos, Thomas J
Liu, Le
Xu, Xuzhong
Wang, Quanguang
Shi, Kejian
Wu, Yiquan
Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study
title Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study
title_full Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study
title_fullStr Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study
title_full_unstemmed Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study
title_short Single and Repeated Intrapleural Ropivacaine Administration: A Plasma Concentration and Pharmacodynamics Study
title_sort single and repeated intrapleural ropivacaine administration: a plasma concentration and pharmacodynamics study
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989531/
https://www.ncbi.nlm.nih.gov/pubmed/33776475
http://dx.doi.org/10.2147/JPR.S295913
work_keys_str_mv AT chenyuanqing singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT caiyaoyao singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT yeyingchao singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT xiayun singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT papadimosthomasj singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT liule singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT xuxuzhong singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT wangquanguang singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT shikejian singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy
AT wuyiquan singleandrepeatedintrapleuralropivacaineadministrationaplasmaconcentrationandpharmacodynamicsstudy